Biocon Biologics Receives EU GMP Certification from HPRA for Its New Biologics Manufacturing Facility

The facility, spread across 340,000-square feet, will enhance our capabilities manifold to manufacture drug substance of our mAbs portfolio and will enable us to serve patients across the globe. This integrated, multi-product facility houses manufacturing suites, analytical testing laboratories and warehousing

logo credit - Biocon Bengaluru
article continues after this advertisement

Biocon Biologics Ltd., a subsidiary of Biocon Ltd. (BSE code: 532523), has received a EU GMP certificate from the Health Products Regulatory Authority (HPRA), Ireland, for its new monoclonal antibodies (mAbs) drug substance manufacturing facility (B3) at Biocon Park, Bengaluru, following a GMP inspection in April 2022.

The facility, spread across 340,000-square feet, will enhance our capabilities manifold to manufacture drug substance of our mAbs portfolio and will enable us to serve patients across the globe. This integrated, multi-product facility houses manufacturing suites, analytical testing laboratories and warehousing.

Upon successful completion and qualification in 2021, it was awarded the Facility of the Year Award (FOYA) with a Honorable Mention, by the International Society for Pharmaceutical Engineering’s (ISPE).

Market Times News update

Shares of Biocon Ltd was last trading in BSE at ₹313.70 as compared to the previous close of ₹311.20. The total number of shares traded during the day was 252381 in over 2010 trades.

The stock last hit in BSE,

  • Intraday High of ₹ 321.45
  • Intraday low of ₹ 314.10